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Background: The costs of psoriasis to a tertiary-level clinic vary considerably depending on the country of study
and methods used. Hospitalisation and phototherapy have been significant cost components. This study was
performed to estimate the distribution and relative magnitude of the costs of psoriasis to a tertiary-level clinic.
Methods: Based on 233 patients, outpatient and phototherapy visits and the days hospitalised were collected from
the treatment provider’s records. The visit costs represented true costs, used to charge the final payers. Patients
were analysed according to their treatment modalities.
Results: On average, hospitalised patients (3.4%) had 31-fold higher total costs than non-hospitalised patients
(p < 0.0001). The costs of hospitalisations formed 45% of all the treatment costs to the entire study population.
Phototherapy accumulated 19% of the overall treatment costs. Patients receiving biological drugs or both
phototherapy and traditional systemic therapy had the highest costs of treatment.
Conclusions: The current study indicates that a small percentage of all psoriasis patients generate a large
proportion of the overall costs to a tertiary-level hospital. Treatment modality has a significant effect on the
costs to a tertiary-level hospital.
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Psoriasis is a lifelong disease with no known curative treat-
ments. In several studies from different countries, the
prevalence of psoriasis was estimated at 1.5%-2.8% of
women and 2.3%-s2.9% of men [1,2]. Around 10%-30% of
patients with psoriasis also have psoriatic arthritis [3,4]. A
recent review considered only seven studies dealing with
the costs of psoriasis [5]. Psoriasis is is thought to be one
of the most costly dermatological diseases due to its high
prevalence [6]. Estimates of per-patient costs vary consid-
erably depending on disease severity [7,8]. Treatment type
and treatment failure in psoriasis treatments have a sig-
nificant effect on the total costs of psoriasis treatment
[9-11]. Patients with psoriasis are at increased risk of other
serious illnesses, including cardiovascular disease, depres-
sion and increased risk of mortality, increasing the costs
related to psoriasis [12-14].* Correspondence: atmust@utu.fi
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unless otherwise stated.The costs of psoriasis to a tertiary-level clinic vary up
to 20 fold due to the different methods used [5,15-20].
Hospitalisation is a significant cost component in many
psoriasis cost-of-illness studies [5]. In general hospital-
isation is a decreasing trend in psoriasis care [11,21-23].
The proportions between outpatient and hospitalisation
costs vary greatly between different studies. It seems that
treatment patterns in different countries have a signifi-
cant effect on the distribution of costs. There is only one
previous study from Scandinavian social security systems
concerning treatment costs of psoriasis and it was lim-
ited to a one-month follow-up.
Most of the psoriasis cost-of-illness studies have been
conducted in patients with moderate- to-severe psoriasis
though there is up to a fourfold variability in the Psoria-
sis Area Severity Index (PASI) [16-18]. The aim of this
study was to estimate the distribution of costs and the
cost of psoriasis treatment in a tertiary-level clinic.tral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Patient sample
The sample was based on psoriasis patients who had vis-
ited the dermatology clinic in Turku University Hospital
(TUH) between 1 October 2009 and 30 September 2010
and were diagnosed as having psoriasis (Ps) or psoriatic
arthritis (PsA). In the Finnish healthcare system, patients
with mild psoriasis are usually treated at primary health
care settings and only moderate-to-severe cases are re-
ferred to a tertiary-level clinic for further treatment. PsA
patients visit the dermatology clinic because of skin
symptoms and receive only dermatological treatment
from the dermatology clinic; rheumatologists or inter-
nists in other clinics treat possible joint problems. Of
the 498 patients attending the clinic during the study
period, 428 had psoriasis and 70 had psoriatic arthritis.
The patients were sent a questionnaire by mail; the mail-
ing was sent again to those who did not respond initially.
A total of 262 patients completed the questionnaire
(52.6% of the total study sample). Patient selection is de-
scribed in more detail by Mattila et al. [24].
Ethical consideration
The ethical committee of The Hospital District of South-
west Finland approved the study. The patients received a
written description of the sampling procedure and study
purpose, as well as the planned use and storage of the in-
formation they were to provide. This was followed by a
description of the subject’s rights according to the
Helsinki declaration. The patients were asked to give writ-
ten consent to use their medical records for the study.
Clinical data
Of the 262 subjects, 29 patients did not give written con-
sent for the right to use their medical records. Clinical in-
formation was collected from the medical records of 233
subjects who gave consent, for the same time period that
was covered in the questionnaire data. Outpatient and
phototherapy visits and the days hospitalised were col-
lected from the treatment provider’s records. Different
types of outpatient visits and hospitalisation days have
varying costs. There were 12 types of outpatient visits.
Each cost item is based on true costs, which are used to
charge the local communities that finally cover the costs
of their residents (Additional file 1). The costs include all
medications, medical equipment, time used by doctors
and other medical staff members and other expenses of
the tertiary-level clinic, during outpatient visits, photo-
therapy or hospitalisation. During outpatient visits medi-
cations are usually not provided. However, infusible
biologic medications (infliximab) can be administered dur-
ing an outpatient visit. Other biologicals and drugs are
purchased by patients from general pharmacies without
any costs to the clinic, and thus, their costs were notincluded in this study. The costs for each visit type and
hospitalisation were obtained from the hospital adminis-
tration (Additional file 1). The actual costs per patient of
laboratory and pathology tests were separately collected
from the records as they are separately charged from the
local communities. The data consisted of every test or-
dered by the dermatology clinic during the study period.
A phototherapy visit had two different cost categories de-
pending on the given phototherapy type (bath-PUVA,
UVB). The costs were applied to each visit category col-
lected from the patient records and were used for all cost
computations.
The Finnish Social Insurance Institute (FSII) provided
information on the medications used by patients. Patients
were divided into subgroups according to their treatment
modalities, as following: 1) only topical treatment (includ-
ing vitamin-D-analogues, corticosteroids, creams and
combinations of these), 2) phototherapy (UVB or PUVA),
3) traditional systemic medications (acitretin, cyclosporin,
and methotrexate), 4) combination treatment (treatments
from both groups 2 and 3 and 5) biological medications
(adalimumab, etanercept, infliximab, and ustekinumab).
Patients in groups 2–5 may have also received topical
treatments and patients in group 5 may have also received
phototherapy and/or traditional systemic medications. A
patient could only be in one group as described above.
The PASI score and the diagnosis International Classi-
fication of Diseases (ICD-10) code of Ps (L40.0) or PsA
(L40.5) were extracted from clinical records to classify
the severity and the type of psoriasis. If there were many
PASI values recorded from the same patient, the mean
value for the study period was calculated and used in the
analysis. Patients were also divided into subgroups for
further assessment by diagnosis of psoriasis (psoriasis
and psoriatic arthritis) and the severity of psoriasis.
Statistical analyses
The statistical evaluation of the data was based on a chi-
square test for proportions and a t test for means. The
Pearson coefficients of correlation were used to examine
the degree of relationship between two continuous vari-
ables. Linear regression models were used to study how
different background factors affected the variation in treat-
ment cost estimates. The distribution of the overall treat-
ment costs were skewed so the data were converted to
close to a normal distribution by natural logarithmic
transformation and used as a dependent variable. In the
analysis of the subgroup with PASI values, all patients
without recorded PASI values were excluded. When ana-
lysing the subgroups with recorded PASI values (72 pa-
tients), patients were divided by the median value to more
severe (PASI more than 5.5 [n = 37] and less severe psoria-
sis [PASI less or equal than 5.5, n = 35]). Only a few pa-
tients had PASI values above 10; using such a high index
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severe Ps patients, which is too small for statistical
analysis.
Results
There were only minor differences in the patient charac-
teristics of different treatment modality groups (Table 1).
The annual cost of tertiary-level treatment per patient
with psoriasis varied widely, from €32 to €43 842, with a
mean of €1419 (Table 2). Half of the patients had costs
less than €600 and 95% of patients had costs less than
€2500. Patients with more severe psoriasis had on
average significantly (p < 0.05) higher treatment costs
(€2683) than patients with less severe psoriasis (€562).
Patients receiving combination therapy or biological
medications had the highest total costs (Table 2). Only
one patient received an infusible biologic medication
(infliximab) during outpatient visits. Patients with psori-
atic arthritis had slightly but non-significantly lower total
costs than patients with psoriasis.
A great majority of patients had only outpatient visits
to the clinic. Only eight patients (3.4%) were hospitalised
because of psoriasis during the study period, for an aver-
age of 7 days. However, the costs of these hospitalisa-
tions formed 45% of all the treatment costs in the entire
study population. On average, hospitalised patients had
costs that were 31-fold higher than non-hospitalised pa-
tients (p < 0.0001). Patients from all different treatment
modality groups had been hospitalised; however, patients
receiving combination therapy or biological medications
had higher costs of hospitalisation (Table 2). All the hos-
pitalised patients were in the more severe (PASI > 5.5)
psoriasis group (p < 0.01). The hospitalised patients also
had more outpatient visits but they received less photo-
therapy than non-hospitalised patients. Females were
more likely to be hospitalised (p < 0.05).
Approximately a third of the patients received photo-
therapy and on average they received 14.8 phototherapy
sessions per year. Phototherapy accounted for 20% of
the overall treatment costs. The patients who received
phototherapy had higher total costs than those who were
treated with topical treatments only, but lower costsTable 1 Patient characteristics according to treatment modali







Male 49% 57% 55%
Mean age 56.8 52.9 63.3*




Mean PASI (n = 71) 5.8 7.3 5.4
*=p < 0.05, otherwise non-significant.than patients in the other treatment modality groups
(Table 2).
In a linear regression model when the effects of other
factors were simultaneously controlled, being hospita-
lised and receiving phototherapy were the strongest pre-
dictors of higher treatment costs. Increasing age and
income level were also significantly related to increasing
costs. Sex and type of psoriasis (Ps or PsA) had a minor
and non-significant effect on overall treatment costs
(Table 3).
Discussion
Overall, the treatment costs of psoriasis are mainly gen-
erated by only a small proportion of patients who have
more severe disease and particularly those that have
been hospitalised. The more severe cases who are hospi-
talised are also at higher risk of treatment failure, and
failure has been shown to be a strong predictor of in-
creased costs [9,10]. Consistent with our findings, in
previous studies by Finzi et al. and Steinke et al., [11,25]
the great majority of the overall costs were generated by
a small proportion of patients. Although hospitalisation
has been a decreasing trend in psoriasis care [21-23],
every effort to reduce hospitalisation days further would
mean significant cost reductions [2]. In previous studies,
hospitalisation has been estimated to be a more effective
way of treating psoriasis than outpatient treatment [26].
In a more recent study, Steinke et al. [11] suggested that
hospitalised patients require extensive treatments after
leaving the hospital and reported a short time to relapse
after hospitalisation, thus questioning the effectiveness
of hospitalisation.
The proportion of hospitalisation of the total costs has
varied considerably in previous studies [11,15-19]. In the
study by Sohn et al. [19], the cost for hospitalisation was
almost fourfold greater than that estimated for hospital-
isation in our study. In their study, hospitalisation repre-
sented more than 80% of the total costs to a hospital,
which was almost twice the proportion in the current
study. Conversely, in a Swedish study [17], the hospital-
isation costs were only 3% of the total costs to the hos-
pital. The differences in the magnitudes and proportionsties and to all patients (all treatment modalities were
ns with the t-test and chi-square test for proportions)











Table 2 Annual costs (€) of psoriasis treatments per cost items for each treatment modality and to all patients













Phototherapy costs 0 755.5§ 0 764.6§ 112.9§ 265.9
Other outpatient
costsa
340.7 382.4 453.0 444.1 4350.1** 468.8
Pathology costs 16.0 11.4 19.1 18.0 36.0 66.2
Laboratory costs 24.9 19.1 102.1*** 71.7*** 62.4*
Hospitalisation costs 177.7 211.6 848.3 2509.2 4611.8* 617.9
Total costs 559.4 1381.3** 1422.4 3807.5** 6914.6*** 1419.0
a = Includes all outpatient visit costs, except those of phototherapy visits.
§ = Not applicable * = p < 0.05, ** = p < 0.01, *** = p < 0.001, otherwise non-significant.
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due to patient selection. In some studies [15,16,19], the
patient samples have included mainly or only subjects
with very severe psoriasis. Patients with more severe dis-
ease are more likely to be hospitalised and more likely to
receive more intensive, longer lasting and costly treat-
ments, which was also observed in the present study.
When assessing the total costs of psoriasis, the cost
estimates per visit or per day have a significant effect on
the final cost. Our study was based on the actual cost used
to charge the local communities. The diagnostic-related
group unit costs per hospitalised day in this study were
higher than the ones used in earlier studies [11,16,17,19].
This increased the proportion of hospitalisation costs in
the current study compared with other studies.
The sample of patients in the present study could be ex-
pected to represent typical tertiary-level patients in
Finland as all patients who had visited the TUH dermatol-
ogy clinic with a psoriasis diagnosis during the period of
one year were included without any selection. Thus, the
whole variety of psoriasis cases was included. In Ghatne-
kar et al. [17], the costs were based on observations from
a period of one month—November-December, the time
when psoriasis is expected to flare in Scandinavian coun-
tries. A follow-up period of one month may also be too
short to catch various patient cases, which may be theTable 3 Linear regression model for studying the effects
of the background factors on total costs
Background factor Beta-value p<
Male −0.054 0.591
Age 0.016 0.000
Disease duration 0.000 0.893
Income level 0.023 0.026




ln(1+ total costs) as dependent variable.reason why their sample included only one patient who
had been hospitalised. Longer follow-up time could be ex-
pected to produce more stable cost estimates and decrease
the possible effect of the fluctuating nature of psoriasis.
In Ghatnekar et al. [17], one-fifth of the costs were from
biologic medication whereas in our study only one person
received biologic medication during outpatient visits. It is
not clear how big a proportion of the patients in the
Swedish study received biologics during treatment visits
and how many had them administered at home; thus a
direct comparison of the findings is not possible. Because
only biologics that were infused in the hospital during an
outpatient visit or while the patient was hospitalised were
considered, the outpatient costs for the biologic treatment
were high, because the cost of infliximab was included in
the visit cost. In our recently published study [27], the
costs of biologic medications were significant and com-
prised 45% of the total costs of medications. For the pa-
tients receiving them, an annual average cost of €15 000
was estimated. In Finland, biologics administered by pa-
tients themselves are reimbursed by the FSII and thus do
not comprise costs to a tertiary-level clinic. This kind of
reimbursement system may have led to reduced use of
infusible biologics and favoured the self-administrable bio-
logics that have no costs to the dermatology clinic.
The introduction of biologics has been shown to in-
crease the costs of medication, but to reduce the other
treatment costs especially in high-need patients [28]. In
our study the hospitalisation rates and overall treatment
costs to a tertiary-level clinic were not significantly lower
for patients receiving biologic medications. This may be
due to using biologic medications only in patients with
already high overall costs, and the high outpatient costs
may have been partly due to the patient receiving inflixi-
mab in an outpatient setting. Our cross-sectional study
design did not allow for further analysis on the impact
of initiating biologic medications, which may have added
to the overall treatment costs.
In studies [15,18] where the PASI-values are very high,
only the most severe psoriasis patients have been selected
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sis has a tendency to flare and fluctuate so studies of pa-
tients with very high PASI values may overestimate the
total costs as patients with a current flare need more treat-
ments than patients who are in remission. Longer follow-
up time decreases the effect of the fluctuation on the costs
for care. In a recent study by Steinke et al., the PASI values
were collected in the same manner as in our study with
the exception of the use of maximum PASI found from
the records during the study period, whereas in this study
all values from the study period were considered and an
arithmetic mean was used as a variable [11]. Only a pro-
portion of patient records in this study included PASI
values. There is no evidence of any selection of patients
with or without PASI recordings, but due to the propor-
tion of missing PASI values these sub-analyses should be
considered with more caution.
Phototherapy may be a significant cost burden. How-
ever, the cost estimates of phototherapy in different stud-
ies have varied greatly [15-17]. Our findings were close to
those of the Swedish study [17] in which almost a third of
the costs were from phototherapy. In some studies, photo-
therapy has formed less than a tenth of the treatment
costs [15,16]. Large differences in phototherapy costs may
be due to unit costs used in different studies. Photother-
apy is time consuming and requires other resources from
the provider. In the present study, all unit costs were
based on actual costs, obtained from the registers, which
are also used to charge the final payers. Thus, direct com-
parison of the present findings with previous studies
[15,16] which may have used rough cost approximations,
may be problematic.
The present study data was based on actual numbers
of various types of visits for the period of one year col-
lected from the records, which could be expected to pro-
duce reliable estimates. In comparison, in Ghatnekar
et al. [17], the numbers of outpatient visits for one year
were extrapolated from data for one month, and the
numbers of outpatient visits obtained from hospital re-
cords were four times the numbers estimated by the pa-
tients in the study.
There are no secondary-level hospitals with dermatology
clinics in the administrative region where the current
study was performed. If available, patients with moderate-
level psoriasis would probably have been at least partly
treated in secondary-level clinics. Consequently, the sam-
ple may have more patients with moderate psoriasis than
many other studies with a tertiary-level setting, which may
affect also the average cost estimates. Ghatnekar et al. [17]
has shown that treatment costs for an average patient with
psoriasis in secondary-level hospitals were almost half of
those in tertiary-level hospitals. The disease severity of our
patients, based on PASI values, was approximately the
same as the overall severity of the patients in secondaryand tertiary-level hospitals [17], indicating that the present
study patients represent the whole variety of moderate to
severe psoriasis cases in the hospital district, although the
sample was derived from the records of a tertiary-level
clinic.
Conclusions
In previous studies, the cost estimates for psoriasis varied
greatly between studies conducted in different societies.
There is a need to harmonize the study field to be able to
compare the results of different studies [5]. Decreasing
hospitalisation may result in a significant cost reduction.
The current study indicates that a small percentage of all
psoriasis patients generate a large proportion of the overall
costs.
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